Truvada (TDF/FTC)
Fixed-dose combination of tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg. Backbone of HIV treatment regimens and the original FDA-approved HIV PrEP (2012). One pill once daily with or without food. Dose-limiting PK is tenofovir's plasma half-life (~17h) and intracellular TFV-DP half-life (~50h). See component entries for full PK of each moiety.
Projected serum levels — 1 pill (≈ 500 mg), once daily
Maintenance schedule: 1 pill (≈ 500 mg) once daily (oral).
Modeled steady state after ~1 days: peak ≈ 189 mg, trough ≈ 9.7 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Antiretroviral
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 4.9 h
- Common dose
- 1 pill (≈ 500 mg)
- Suggested maximum
- 1 pill/day
- Reference dose range
- 0.50–1 pill (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
Landmark iPrEx trial establishing daily oral TDF/FTC as effective HIV pre-exposure prophylaxis, with 44% overall reduction and >90% in adherent participants.
-
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana
TDF2 study confirming TDF/FTC PrEP efficacy (62% reduction) in heterosexual men and women, broadening clinical applicability.
2 published studies referenced in the app, each with a plain-language summary.